167 related articles for article (PubMed ID: 33159459)
1. Trichomonas vaginalis serostatus and prostate cancer risk in Egypt: a case-control study.
Saleh NE; Alhusseiny SM; El-Zayady WM; Aboelnaga EM; El-Beshbishi WN; Saleh YM; Abou-ElWafa HS; El-Beshbishi SN
Parasitol Res; 2021 Apr; 120(4):1379-1388. PubMed ID: 33159459
[TBL] [Abstract][Full Text] [Related]
2. Trichomonas vaginalis infection and prostate-specific antigen concentration: Insights into prostate involvement and prostate disease risk.
Langston ME; Bhalla A; Alderete JF; Nevin RL; Pakpahan R; Hansen J; Elliott D; De Marzo AM; Gaydos CA; Isaacs WB; Nelson WG; Sokoll LJ; Zenilman JM; Platz EA; Sutcliffe S
Prostate; 2019 Oct; 79(14):1622-1628. PubMed ID: 31376187
[TBL] [Abstract][Full Text] [Related]
3. Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer.
Sutcliffe S; Giovannucci E; Alderete JF; Chang TH; Gaydos CA; Zenilman JM; De Marzo AM; Willett WC; Platz EA
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):939-45. PubMed ID: 16702374
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study.
Stark JR; Judson G; Alderete JF; Mundodi V; Kucknoor AS; Giovannucci EL; Platz EA; Sutcliffe S; Fall K; Kurth T; Ma J; Stampfer MJ; Mucci LA
J Natl Cancer Inst; 2009 Oct; 101(20):1406-11. PubMed ID: 19741211
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Seropositivity to Trichomonas vaginalis between Men with Prostatic Tumor and Normal Men.
Kim JH; Moon HS; Kim KS; Hwang HS; Ryu JS; Park SY
Korean J Parasitol; 2019 Feb; 57(1):21-25. PubMed ID: 30840795
[TBL] [Abstract][Full Text] [Related]
6. Trichomonas vaginalis infection and risk of prostate cancer: associations by disease aggressiveness and race/ethnicity in the PLCO Trial.
Marous M; Huang WY; Rabkin CS; Hayes RB; Alderete JF; Rosner B; Grubb RL; Winter AC; Sutcliffe S
Cancer Causes Control; 2017 Aug; 28(8):889-898. PubMed ID: 28669054
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of effect modification by Toll-like receptor 4 variation on the association between Trichomonas vaginalis serostatus and prostate cancer.
Chen YC; Huang YL; Platz EA; Alderete JF; Zheng L; Rider JR; Kraft P; Giovannucci E; Sutcliffe S
Cancer Causes Control; 2013 Jan; 24(1):175-80. PubMed ID: 23179660
[TBL] [Abstract][Full Text] [Related]
8. Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial.
Sutcliffe S; Alderete JF; Till C; Goodman PJ; Hsing AW; Zenilman JM; De Marzo AM; Platz EA
Int J Cancer; 2009 May; 124(9):2082-7. PubMed ID: 19117055
[TBL] [Abstract][Full Text] [Related]
9. Persistence of Trichomonas vaginalis serostatus in men over time.
Sutcliffe S; Alderete JF; Neace C; Joyce PA; Gaydos CA; Huth JI; Mucci LA; Signorello LB
Cancer Causes Control; 2015 Oct; 26(10):1461-6. PubMed ID: 26223890
[TBL] [Abstract][Full Text] [Related]
10. An iatrogenic confounding variable.
Albertsen PC
J Natl Cancer Inst; 2009 Oct; 101(20):1368-9. PubMed ID: 19741210
[No Abstract] [Full Text] [Related]
11. Trichomonas vaginalis as a cause of urethritis in Malawian men.
Hobbs MM; Kazembe P; Reed AW; Miller WC; Nkata E; Zimba D; Daly CC; Chakraborty H; Cohen MS; Hoffman I
Sex Transm Dis; 1999 Aug; 26(7):381-7. PubMed ID: 10458630
[TBL] [Abstract][Full Text] [Related]
12. Trichomonas vaginalis infection and risk of advanced prostate cancer.
Shui IM; Kolb S; Hanson C; Sutcliffe S; Rider JR; Stanford JL
Prostate; 2016 May; 76(7):620-3. PubMed ID: 26818005
[TBL] [Abstract][Full Text] [Related]
13. A prospective study of Trichomonas vaginalis and prostate cancer risk among African American men.
Fowke JH; Han X; Alderete JF; Moses KA; Signorello LB; Blot WJ
BMC Res Notes; 2016 Apr; 9():224. PubMed ID: 27091219
[TBL] [Abstract][Full Text] [Related]
14. Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer.
Vicier C; Werner L; Chipman J; Harshman LC; Patil DH; Fichorova RN; Rider JR; Sanda MG; Mucci LA; Sweeney CJ
Clin Genitourin Cancer; 2019 Feb; 17(1):32-37. PubMed ID: 30348512
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of circulating antibody response to Trichomonas vaginalis: clinical and diagnostic implications.
Ton Nu PA; Rappelli P; Dessì D; Nguyen VQ; Fiori PL
Sex Transm Infect; 2015 Dec; 91(8):561-3. PubMed ID: 25887282
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to Trichomonas vaginalis surface glycolipid.
Bastida-Corcuera FD; Singh BN; Gray GC; Stamper PD; Davuluri M; Schlangen K; Corbeil RR; Corbeil LB
Sex Transm Infect; 2013 Sep; 89(6):467-72. PubMed ID: 23785040
[TBL] [Abstract][Full Text] [Related]
17. Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responses.
Twu O; Dessí D; Vu A; Mercer F; Stevens GC; de Miguel N; Rappelli P; Cocco AR; Clubb RT; Fiori PL; Johnson PJ
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8179-84. PubMed ID: 24843155
[TBL] [Abstract][Full Text] [Related]
18. Association between Trichomonas vaginalis and prostate cancer mortality.
Tsang SH; Peisch SF; Rowan B; Markt SC; Gonzalez-Feliciano AG; Sutcliffe S; Platz EA; Mucci LA; Ebot EM
Int J Cancer; 2019 May; 144(10):2377-2380. PubMed ID: 30242839
[TBL] [Abstract][Full Text] [Related]
19. Epitopes of the highly immunogenic Trichomonas vaginalis α-actinin are serodiagnostic targets for both women and men.
Neace CJ; Alderete JF
J Clin Microbiol; 2013 Aug; 51(8):2483-90. PubMed ID: 23616456
[TBL] [Abstract][Full Text] [Related]
20. Serum antibodies to Trichomonas vaginalis in invasive cervical cancer patients.
Yap EH; Ho TH; Chan YC; Thong TW; Ng GC; Ho LC; Singh M
Genitourin Med; 1995 Dec; 71(6):402-4. PubMed ID: 8566984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]